List of works - Erwin Dreesen

A Population Pharmacokinetic and Exposure-Response Model of Golimumab for Targeting Endoscopic Remission in Patients With Ulcerative Colitis

scientific article published on 01 March 2020

Adequate Infliximab Exposure During Induction Predicts Remission in Paediatric Patients With Inflammatory Bowel Disease

scientific article published on 01 June 2019

Anti-infliximab antibody concentrations can guide treatment intensification in patients with Crohn's disease who lose clinical response.

scientific article

Antibodies Toward Vedolizumab Appear from the First Infusion Onward and Disappear Over Time

scientific article published in December 2017

Current Practices for Therapeutic Drug Monitoring of Biopharmaceuticals in Pediatrics

scientific article published on August 2017

Effectiveness and safety of switching IBD patients from the originator to the biosimilar infliximab

Efficacy, Pharmacokinetics, and Immunogenicity is Not Affected by Switching From Infliximab Originator to a Biosimilar in Pediatric Patients With Inflammatory Bowel Disease

scientific article published on 01 June 2019

Harmonization of Infliximab and Anti-Infliximab Assays Facilitates the Comparison Between Originators and Biosimilars in Clinical Samples

scientific article published on 7 March 2016

Higher Infliximab Trough Levels Are Associated With Better Outcome in Paediatric Patients With Inflammatory Bowel Disease

scientific article published on 01 November 2018

How, When, and for Whom Should We Perform Therapeutic Drug Monitoring?

scientific article published on 04 October 2019

Influence of Drug Exposure on Vedolizumab-Induced Endoscopic Remission in Anti-Tumour Necrosis Factor [TNF] Naïve and Anti-TNF Exposed IBD Patients

scientific article published on 01 March 2020

Letter: overcoming secondary loss of response to infliximab-it is not the drug, it is how you use it! Authors' reply

scientific article published on 01 November 2018

Meropenem Target Attainment and Population Pharmacokinetics in Critically Ill Septic Patients with Preserved or Increased Renal Function

scientific article published on 08 January 2022

Modelling of the Relationship Between Infliximab Exposure, Faecal Calprotectin, and Endoscopic Remission in Patients with Crohn's Disease

scientific article published on 15 May 2020

Monitoring a Combination of Calprotectin and Infliximab Identifies Patients With Mucosal Healing of Crohn's Disease

scientific article published on 22 May 2019

Optimising infliximab induction dosing for patients with ulcerative colitis

scientific article published on 10 February 2019

Peak Concentrations of Ustekinumab After Intravenous Induction Therapy Identify Patients With Crohn's Disease Likely to Achieve Endoscopic and Biochemical Remission

scientific article published on 25 February 2020

Pharmacodynamic monitoring of biological therapies in chronic inflammatory diseases

scientific article published on 03 October 2018

Pharmacokinetic Modeling and Simulation of Biologicals in Inflammatory Bowel Disease: The Dawning of a New Era for Personalized Treatment

scientific article published on 7 March 2016

Pharmacokinetics and target attainment of intravenous posaconazole in critically ill patients during extracorporeal membrane oxygenation

scientific article published in 2021

Practical recommendations for the use of therapeutic drug monitoring of biopharmaceuticals in inflammatory diseases.

scientific article published on 3 October 2017

Reply

Response to Letter to the Editor

scientific article published on 18 March 2020

Subcutaneous Absorption Contributes to Observed Interindividual Variability in Adalimumab Serum Concentrations in Crohn's Disease: A Prospective Multicentre Study

scientific article published on 01 September 2019

Ustekinumab Exposure-outcome Analysis in Crohn's Disease Only in Part Explains Limited Endoscopic Remission Rates

scientific article published on 01 July 2019

Variability in Golimumab Exposure: A 'Real-Life' Observational Study in Active Ulcerative Colitis